Therapeutic Class
Direct-Acting Antiviral (DAA)
NS5B Polymerase Inhibitor

Indication
Treatment of chronic hepatitis C virus (HCV) infection in adults, as part of combination antiviral therapy, in accordance with WHO-recommended treatment guidelines.

Dosage & Administration
400 mg once daily, in combination with other antiviral agents, or as prescribed by a healthcare professional.

To be used strictly as part of a guideline-recommended HCV treatment regimen.

Storage
Store below 30°C in a dry place, protected from light and moisture.

Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO treatment guidelines.

*This combination is under patent protection in several markets. Supply, manufacture, or distribution is subject to applicable patent laws and local regulatory approvals.